Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech IncfiledCriticalJanssen Biotech Inc
Priority to NZ627451ApriorityCriticalpatent/NZ627451A/en
Priority claimed from NZ610460Aexternal-prioritypatent/NZ610460A/en
Publication of NZ627451ApublicationCriticalpatent/NZ627451A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Disclosed is a use of a peptide immunogen in the preparation of a medicament for treating a patient, wherein the patient is being treated with a specific antibody containing composition, wherein antibody is susceptible to cleavage by one or more proteases associated with the specific disease being treated, and wherein the peptide is a peptide fragment or analogue representative of a proteolytic cleavage site on IgG produced by the one or more proteases associated with the specific disease being treated by antibody therapy.
ANTIBODY OF THE PEPTIDE RELATED TO THE CALCITONINE GENE (CGRP), PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF THE ANTIBODY TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT PAIN OR MIGRANE PAIN AND ANOGEN ANOGEN FRAGMENT
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
Legal Events
Date
Code
Title
Description
PSEA
Patent sealed
RENW
Renewal (renewal fees accepted)
Free format text:
PATENT RENEWED FOR 3 YEARS UNTIL 19 NOV 2017 BY AJ PARK